SITE007-0231

SITE007 (JPN) › SITE007-0231

SITE007-0231

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2026-05-25

enrolled

AEs

6

Serious

1

Dropout signal

–

Adverse events

6

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 96); relationship: not assessed

mild assessed

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 96); relationship: not assessed

mild assessed

Grade 3 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 85); relationship: not assessed; serious criteria: hospitalization

severe serious under_review

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 72); relationship: NOT RELATED

moderate assessed

Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2023-02-02 (study day 57); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 50); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.